Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
Posted on 2019-10-24 - 13:55
Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Cai, Wen; Cai, Biao; Zhou, Juan; Chen, Yonghui; Zhang, Jin; Huang, Yiran; et al. (2019). Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.4711409.v1
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
AUTHORS (8)
WC
Wen Cai
BC
Biao Cai
JZ
Juan Zhou
YC
Yonghui Chen
JZ
Jin Zhang
YH
Yiran Huang
WX
Wei Xue
JH
Jiwei Huang